Karen Taylor Research Group

Research in a Nutshell

Breast cancer remains a global health challenge with 7.8 million new cases annually. Despite advances in treatment and screening it remains the leading cause of female cancer death globally and in the UK. There remains an urgent need for precision medicine approaches to discover and validate novel prognostic and predictive patient stratification models which are key to future clinical trial design. 

Our research focuses on the development and validation of biomarkers, integrating multi-omic approaches and digital/AI-based pathology. To achieve this our research is based on a large curated breast cancer translational pathology biobank of multiple well-annotated phase 3 clinical trials, which allow us to transform large datasets in to clinically relevant predictions at an individual patient level.

• Professor David Cameron, The University of Edinburgh
• Professor Peter Hall, The University of Edinburgh
• Professor Ian Kunkler, The University of Edinburgh
• Dr Arran Turnbull, The University of Edinburgh
• Professor Iain MacPherson, The University of Glasgow
• Professor Rob Stein, University College London
• Professor Daniel Rea, University of Birmingham
• Professor Robert Hills, University of Oxford
• Dr Roberto Salgado, Peter MacCallum Cancer Centre, Australia & ZAS Hospitals, Belgium
• Dr Mattias Rantalainen, Karolinska Institute, Sweden

• Breast Cancer Research Foundation
• Swedish Research Council
• NHS Lothian Charity